Emergent BioSolutions wins $54 million ASPR VIGIV contract option; secures $6.6 million ACAM2000 orders from international government partner
Reuters
Yesterday
Emergent BioSolutions wins $54 million ASPR VIGIV contract option; secures $6.6 million ACAM2000 orders from international government partner
Emergent secured a contract award valued at about USD 54.0 million to deliver CNJ-016 (VIGIV) to the U.S. Administration for Strategic Preparedness and Response under an option in an existing 10-year contract.
New incremental orders valued at USD 6.6 million were received from an international government partner for ACAM2000 smallpox vaccine.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603251615PRIMZONEFULLFEED9678687) on March 25, 2026, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.